ALTMAN MICHAEL SETH has filed 5 insider transactions across 3 companies since June 2023.
Most recent transaction: a grant/award of 45000 shares of Nautilus Biotechnology, Inc. ($NAUT) on June 14, 2024.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| June 14, 2024 | Nautilus Biotechnology, Inc. | $NAUT | ALTMAN MICHAEL SETH | Director | A | Stock Option (Right to Buy) | 45000 | $0.00 | 45,000.0000 | 0 | 9999.99% | 0.00% |
| June 13, 2024 | Lyra Therapeutics, Inc. | $LYRA | ALTMAN MICHAEL SETH | Not found | A | Stock Option | 30000 | $0.00 | 30,000.0000 | 0 | 9999.99% | 0.00% |
| June 13, 2024 | Perceptive Capital Solutions Corp | $PCSC | ALTMAN MICHAEL SETH | Chief Business Officer | A | Class A ordinary shares | 286250 | $10.00 | 286,250.0000 | 0 | 9999.99% | 0.00% |
| June 30, 2023 | Lyra Therapeutics, Inc. | $LYRA | ALTMAN MICHAEL SETH | Not found | A | Stock Option | 20000 | $0.00 | 20,000.0000 | 0 | 9999.99% | 0.00% |
| June 15, 2023 | Nautilus Biotechnology, Inc. | $NAUT | ALTMAN MICHAEL SETH | Director | A | Stock Option (Right to Buy) | 45000 | $0.00 | 45,000.0000 | 0 | 9999.99% | 0.00% |